NYSE · LLY
Eli Lilly and Company
$1,431.16+$57.46 (+4.18%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
NASDAQ · GRTS · USD
Stock price, earnings
Quote as of Oct 21, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Gritstone bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gritstone bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gritstone bio, Inc. is a clinical-stage biotechnology company focused on pioneering immunotherapies to address various types of cancer and infectious diseases. Its primary product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat a range of solid tumors, specifically including metastatic non-small cell lung cancer, gastroesophageal, bladder, and microsatellite stable colorectal cancers. Gritstone bio is also advancing SLATE, an off-the-shelf immunotherapy candidate aimed at common solid tumors such as metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and those with shared neoantigens. Furthermore, the company is developing CORAL, a SARS-CoV-2 vaccine platform intended to provide broader and more robust immunity against variants by delivering both spike and additional SARS-CoV-2 T cell epitopes. It is also working on a therapeutic vaccine candidate focused on treating and potentially curing human immunodeficiency virus (HIV) infection. Gritstone bio maintains key partnerships, including a strategic collaboration with bluebird bio, Inc., a collaboration agreement with Gilead Sciences, Inc., and a license agreement with Genevant Sciences GmbH. Founded in 2015 and headquartered in Emeryville, California, the company operated as Gritstone Oncology, Inc. until its rebranding to Gritstone bio, Inc. in May 2021.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:59 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 | May 11, 2023 | -$0.30+6.25% vs estimate | $542.00K-82.9% vs estimate |
|---|
| Q4 2022 | Mar 9, 2023 | -$0.30+3.23% vs estimate | $1.33M-54.24% vs estimate |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,431.16+$57.46 (+4.18%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$279.12+$3.92 (+1.42%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 0.7% below the high.
$95.81-$1.75 (-1.8%)
Kiniksa Pharmaceuticals International, plc’s quoted price sits in the upper half of its reported 52-week range, 2.63% below the high.
$8.52-$0.01 (-0.06%)
BioCryst Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.11% below the high.
$3.94-$0.05 (-1.25%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.3% below the high.
$2.24-$0.06 (-2.4%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.78% below the high.
$7.52-$0.28 (-3.53%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.86% below the high.
$8.26-$0.27 (-3.21%)
Atara Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.89% below the high.
